Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies-Reference-Cited by-同舟云学术

Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies

Published:2019-07-15 Issue:2 Volume:200 Page:133-139
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Kaner Robert J.¹²^ORCID,Bajwa Ednan K.³,El-Amine Moustapha⁴,Gorina Eduard⁵,Gupta Renu⁶,Lazarus Howard M.⁷,Luckhardt Tracy R.⁸,Mouded Majd⁹,Posada Kaity¹⁰,Richeldi Luca¹¹,Stauffer John¹²,Tutuncu Ahmet¹³,Martinez Fernando J.¹

Affiliation:

1. Division of Pulmonary and Critical Care Medicine, Department of Medicine, and

2. Department of Genetic Medicine, Weill Cornell Medicine, New York, New York

3. Merck & Co., Inc., Kenilworth, New Jersey

4. AstraZeneca plc, Wilmington, Delaware

5. Pliant Therapeutics, Inc., South San Francisco, California

6. Promedior, Inc., Lexington, Massachusetts

7. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut

8. Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama

9. Biogen, Inc., Cambridge, Massachusetts

10. Acceleron Pharma, Inc., Cambridge, Massachusetts

11. Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

12. Genentech, Inc., South San Francisco, California; and

13. Respivant Sciences, Inc., San Diego, California

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.201903-0592PP

Reference44 articles.

1. Predicting Survival in Idiopathic Pulmonary Fibrosis

2. Idiopathic Pulmonary Fibrosis

3. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

4. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

5. Assessing the Generalizability of Randomized Trial Results to Target Populations

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Added Power of Synthetic Control Groups: Challenging Conventional Wisdom and Trial Design in Idiopathic Pulmonary Fibrosis Research;American Journal of Respiratory and Critical Care Medicine;2023-09-01

2. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF);BMJ Open Respiratory Research;2023-08

3. Efficient transfected liposomes co-loaded with pNrf2 and pirfenidone improves safe delivery for enhanced pulmonary fibrosis reversion;Molecular Therapy - Nucleic Acids;2023-06

4. Nanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis;BioTech;2023-05-05

5. A Phase IIb Randomized Clinical Study of an Anti-α_vβ₆ Monoclonal Antibody in Idiopathic Pulmonary Fibrosis;American Journal of Respiratory and Critical Care Medicine;2022-11-01